Veroscience LLC

Louisiana State University and Agricultural & Mechanical College

Ergo Research Corporation

Ergo Science Incorporated

The General Hospital Corporation

Other

The Rowland Institute for Science

Agricultural and Mechanical College

Geneva Pharmaceuticals, Inc.

Pliva D.d.

Board of Supervisors of Louisiana Business and Agricultural and

The General Hopital Corporation

The General Hospital Corporation/board of Supervisors of Louisiana State

The Board of Supervisors of Louisana State and Agricultural and

Anthony H Cincotta

Albert H Meier

Louis Cincotta

Alex Nivorozhkin

Nelson Landrau

Craig Michael Bowe

Laura Jean Weston

Paul Clark Stearns

John M Wilson

Tayyaba Hasan

Christopher L Pelloni

Manuel Cincotta

Paul Clark Steams

Donn D Martin

Sandra Louise Tigner

Christopher Eric Runice

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Composition and method for treating metabolic disorders

Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.

Method for inducing tumor regression

The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.

Bromocriptine formulations

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

The present disclosure describes pharmaceutical formulations of bromocriptine and methods of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.

This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.

Method of treating metabolic disorders and depression with dopamine receptor agonists

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Parenteral formulations of dopamine agonists

Growing community of inventors

Andover, MA, United States of America

Anthony H Cincotta